North China Pharmaceutical (SHA:600812) agreed to receive financial services from Jizhong Energy Group Finance for three years, according to a Wednesday disclosure on the Shanghai bourse.
The financial services will include deposit, settlement, credit, intermediary, and cash pooling management services.
Under the deal, the Chinese pharmaceutical company's daily deposits will not exceed 1 billion yuan, while annual credit should be at least 1 billion yuan.
North China Pharmaceutical's shares slipped over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.